Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × talazoparib × Thoracic × Clear all

Phase

Status

Withdrawn 2 Unknown 1 Terminated 1 Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 7 Genitourinary 6 Gynecologic 4 Gastrointestinal 4 Tumor-Agnostic 2 Sarcoma 2 Other hematologic neoplasm 2 Thoracic 1 Plasma cell 1 NET 1 Myeloid 1 Lymphoid 1 Endocrine 1 CNS 1

Conditions

Small Cell Lung Carcinoma 1 Lung Neoplasms 1

Interventions

Carboplatin 169 pembrolizumab 149 Pemetrexed 121 Cisplatin 95 Drug Therapy 57 Paclitaxel 56 Radiotherapy 48 osimertinib 45 durvalumab 43 Specimen Handling 42 Nivolumab 42 Magnetic Resonance Spectroscopy 42 Docetaxel 37 Etoposide 36 atezolizumab 35 Bevacizumab 35 Blood Specimen Collection 32 tislelizumab 30 Radiosurgery 27 Immune Checkpoint Inhibitors 24 130-nm albumin-bound paclitaxel 24 Immunotherapy 22 Gemcitabine 22 cemiplimab 19 aflutinib 19 Injections 18 Cetuximab 16 toripalimab 15 Surgical Procedures, Operative 15 Platinum Compounds 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04170946 2026-03-05

Talazoparib

University Health Network, Toronto

Phase 1 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡